Physician profile
Daniel Storch
NPI 1790740413
$8,461.73
in general payments reported to CMS, 2019-2025
23 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $1,180 · 2021: $1,559 · 2022: $1,016 · 2023: $1,261 · 2024: $1,207 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,049.70 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $961.52 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $882.20 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $761.74 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $716.53 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $658.60 | 2020-2022 | |
| Lundbeck LLC | $648.99 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $527.52 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $512.19 | 2020-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $377.97 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $300.37 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $284.06 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $233.57 | 2023-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $165.84 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $99.55 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $69.13 | 2020-2021 | |
| Noven Therapeutics, LLC | $43.89 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $41.32 | 2019 | |
| Axsome Therapeutics, INC. | $31.15 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $30.12 | 2021 | |
| Owp Pharmaceuticals, INC. | $28.38 | 2019-2022 | |
| Almatica Pharma LLC | $21.11 | 2022 | |
| Shire North American Group INC | $16.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Storch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.